| Type |
Details |
Score |
| Genotype |
| Symbol: |
Brca1/Brca1 Tg(LGB-cre)74Acl/? |
| Background: |
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(Prrx1-Hand2)7Eno/? |
| Background: |
involves: C57BL/6 * CBA |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(HCRT-MJD)1Stak/? |
| Background: |
B6.Cg-Tg(HCRT-MJD)1Stak |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(PF4MER)6Kra/? |
| Background: |
FVB/N-Tg(PF4MER)6Kra |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(IghMyc)22Bri/? Xiap/Xiap |
| Background: |
B6.Cg-Xiap Tg(IghMyc)22Bri |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Kat5/Kat5<+> Tg(IghMyc)22Bri/? Trp53/Trp53<+> |
| Background: |
involves: 129 * C57BL * C57BL/6 * SJL |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(HCRT-MJD)1Stak/? |
| Background: |
involves: C57BL/6 * DBA/1 |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor |
| Background: |
involves: C57BL/6 * FVB/N |
| Zygosity: |
hm |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(IghMyc)186Brn/? Rpl24/Rpl24<+> |
| Background: |
involves: C57BL/LiA * C57BLKS * CBA/BrA |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(MMTV-Cdc37)1Stp/? Tg(MMTV-Myc)141-3Led/? |
| Background: |
involves: C57BL/6 * CD-1 * DBA/2 * FVB/N |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Osr2/Osr2 |
| Background: |
involves: 129S1/Sv * C57BL/6J |
| Zygosity: |
ht |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Mdm4/Mdm4<+> Tg(IghMyc)22Bri/? |
| Background: |
involves: 129S6/SvEvTac * C57BL * C57BL/6 * SJL |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(Vim*R113C)1Tmm/? |
| Background: |
B6.CBA-Tg(Vim*R113C)1Tmm |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Pkd1/Pkd1 |
| Background: |
involves: 129S2/SvPas * C57BL/6 * C57BL/6NTac |
| Zygosity: |
ht |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Pkd1/Pkd1 |
| Background: |
involves: 129S2/SvPas * C57BL/6 * C57BL/6NTac |
| Zygosity: |
ht |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Pkd1/Pkd1 |
| Background: |
involves: 129S2/SvPas * C57BL/6 * C57BL/6NTac |
| Zygosity: |
ht |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Pkd1/Pkd1 |
| Background: |
involves: 129S2/SvPas * C57BL/6 * C57BL/6NTac |
| Zygosity: |
ht |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(Alb1-Ren)3Unc/? |
| Background: |
involves: 129S6/SvEvTac * C57BL/6 |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Apc/Apc<+> Del(15Rr357-Rr303293)2Jta/Del(15Rr357-Rr303293)2Jta |
| Background: |
involves: C57BL/6 |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Plcg2/Plcg2 Tg(IghMyc)22Bri/? |
| Background: |
involves: 129P2/OlaHsd * C57BL * C57BL/6 * SJL |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(APOE-rtTA*M2,tetO-Rgs16)#Tmw/? |
| Background: |
involves: C57BL/6 * DBA |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Plxna4/Plxna4<+> Sema6a/Sema6a<+> |
| Background: |
involves: 129P2/OlaHsd |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(EEF1A1-Socs6)1Pwg/? |
| Background: |
B6.129P2-Tg(EEF1A1-Socs6)1Pwg |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(EEF1A1-Socs6)2Pwg/? |
| Background: |
B6.129P2-Tg(EEF1A1-Socs6)2Pwg |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Bcl2l11/Bcl2l11<+> Tg(IghMyc)22Bri/? |
| Background: |
involves: C57BL/6 * SJL |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Bcl2l11/Bcl2l11 Tg(IghMyc)22Bri/? |
| Background: |
involves: C57BL/6 * SJL |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Bcl2l11/Bcl2l11<+> Tg(IghMyc)22Bri/? |
| Background: |
involves: C57BL/6 * SJL |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Bcl2l11/Bcl2l11 Tg(IghMyc)22Bri/? |
| Background: |
involves: C57BL/6 * SJL |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Bcl2l11/Bcl2l11<+> Tg(IghMyc)22Bri/? |
| Background: |
involves: C57BL/6 * SJL |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Bcl2l11/Bcl2l11 Tg(IghMyc)22Bri/? |
| Background: |
involves: C57BL/6 * SJL |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(Prnp-TARDBP)96Dwc/? |
| Background: |
involves: C57BL/6 * C3H |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(APOE-FGF23*R176Q)#Ack/? |
| Background: |
involves: C57BL/6J * CBA |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(Prnp-TARDBP*M337V)106Dwc/? |
| Background: |
involves: C57BL/6 * C3H |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Apc/Apc<+> Rr21/Rr21<+> |
| Background: |
involves: C57BL/6 |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Trp53/Trp53<+> Tg(IghMyc)22Bri/? |
| Background: |
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL * SJL |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Igs2/Igs2 |
| Background: |
involves: 129S1/Sv * 129X1/SvJ |
| Zygosity: |
hm |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Bok/Bok Tg(IghMyc)22Bri/? |
| Background: |
involves: BALB/cJ * C57BL * C57BL/6 * SJL |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor |
| Background: |
involves: 129 * C57BL/6 |
| Zygosity: |
hm |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Il6/Il6 Tg(H2-K-IL6)2Srj/? |
| Background: |
involves: 129S2/SvPas * C57BL/6 * DBA/2 |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(Prnp-TARDBP)96Dwc/? |
| Background: |
involves: C3H * C57BL/6 |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(Myh6-Mybpc3*)24Rbns/? |
| Background: |
Not Specified |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(Myh6-MYL2*E22K)4Dsc/? |
| Background: |
involves: C57BL/6 * SJL |
| Zygosity: |
ot |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gt(ROSA)26Sor/? Tg(Atoh1-cre)1Bfri/? |
| Background: |
B6.Cg-Gt(ROSA)26Sor Tg(Atoh1-cre)1Bfri/Btar |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(GFAP-tTA)110Pop/? Tg(tetO-DISC1*)1302BPlet/? |
| Background: |
B6.Cg-Tg(GFAP-tTA)110Pop Tg(tetO-DISC1*)1302BPlet |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(Cebpb-tTA)5Bjd/? Tg(tetO-MYC,-OVAL)#Gtgm/? |
| Background: |
B6J.Cg-Tg(Cebpb-tTA)5Bjd Tg(tetO-MYC,-OVAL)#Gtgm |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Trp53/Trp53<+> Tg(IghMyc)22Bri/? |
| Background: |
involves: 129 * C57BL * SJL |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(BCL2)36Wehi/? Tg(IghMyc)22Bri/? Zfp574/Zfp574 |
| Background: |
B6.Cg-Zfp574 Tg(BCL2)36Wehi Tg(IghMyc)22Bri |
| Zygosity: |
cx |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Tg(Rho-cre)2Yzl/? |
| Background: |
involves: 129 * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> |
| Background: |
B6;129-Gt(ROSA)26Sor/J |
| Zygosity: |
ht |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Bienz B |
| Year: |
1984 |
| Journal: |
EMBO J |
| Title: |
Analysis of the gene coding for the murine cellular tumour antigen p53. |
| Volume: |
3 |
| Issue: |
9 |
| Pages: |
2179-83 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Kawauchi D |
| Year: |
2012 |
| Journal: |
Cancer Cell |
| Title: |
A mouse model of the most aggressive subgroup of human medulloblastoma. |
| Volume: |
21 |
| Issue: |
2 |
| Pages: |
168-80 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Gustafson WC |
| Year: |
2014 |
| Journal: |
Cancer Cell |
| Title: |
Drugging MYCN through an allosteric transition in Aurora kinase A. |
| Volume: |
26 |
| Issue: |
3 |
| Pages: |
414-427 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Trimboli AJ |
| Year: |
2008 |
| Journal: |
Cancer Res |
| Title: |
Direct evidence for epithelial-mesenchymal transitions in breast cancer. |
| Volume: |
68 |
| Issue: |
3 |
| Pages: |
937-45 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Christensen CL |
| Year: |
2014 |
| Journal: |
Cancer Cell |
| Title: |
Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. |
| Volume: |
26 |
| Issue: |
6 |
| Pages: |
909-922 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Yoneda Y |
| Year: |
1993 |
| Journal: |
Neurosci Lett |
| Title: |
Selectively high expression of the transcription factor AP1 in telencephalic structures of epileptic E1 mice. |
| Volume: |
161 |
| Issue: |
2 |
| Pages: |
161-4 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Shen-Li H |
| Year: |
2000 |
| Journal: |
Genes Dev |
| Title: |
Essential role for Max in early embryonic growth and development. |
| Volume: |
14 |
| Issue: |
1 |
| Pages: |
17-22 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
ZacarÃas-Fluck MF |
| Year: |
2021 |
| Journal: |
Life Sci Alliance |
| Title: |
The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets. |
| Volume: |
4 |
| Issue: |
5 |
|
|
•
•
•
•
•
|
| Publication |
| First Author: |
Screen M |
| Year: |
2024 |
| Journal: |
Life Sci Alliance |
| Title: |
RNA helicase EIF4A1-mediated translation is essential for the GC response. |
| Volume: |
7 |
| Issue: |
2 |
|
|
•
•
•
•
•
|
| Publication |
| First Author: |
Benitah SA |
| Year: |
2005 |
| Journal: |
Science |
| Title: |
Stem cell depletion through epidermal deletion of Rac1. |
| Volume: |
309 |
| Issue: |
5736 |
| Pages: |
933-5 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Strasser A |
| Year: |
1993 |
| Journal: |
Oncogene |
| Title: |
E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. |
| Volume: |
8 |
| Issue: |
1 |
| Pages: |
1-9 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Wang B |
| Year: |
2019 |
| Journal: |
Cell Rep |
| Title: |
Induction of Pluripotent Stem Cells from Mouse Embryonic Fibroblasts by Jdp2-Jhdm1b-Mkk6-Glis1-Nanog-Essrb-Sall4. |
| Volume: |
27 |
| Issue: |
12 |
| Pages: |
3473-3485.e5 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Gu Y |
| Year: |
2017 |
| Journal: |
Cancer Cell |
| Title: |
Stabilization of the c-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma. |
| Volume: |
32 |
| Issue: |
1 |
| Pages: |
115-128.e7 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Fan H |
| Year: |
1996 |
| Journal: |
FEBS Lett |
| Title: |
A link between ferritin gene expression and ribonucleotide reductase R2 protein, as demonstrated by retroviral vector mediated stable expression of R2 cDNA. |
| Volume: |
382 |
| Issue: |
1-2 |
| Pages: |
145-8 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Wanzel M |
| Year: |
2008 |
| Journal: |
Nat Cell Biol |
| Title: |
A ribosomal protein L23-nucleophosmin circuit coordinates Mizl function with cell growth. |
| Volume: |
10 |
| Issue: |
9 |
| Pages: |
1051-61 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Arvanitis C |
| Year: |
2005 |
| Journal: |
Cancer Lett |
| Title: |
Conditionally MYC: insights from novel transgenic models. |
| Volume: |
226 |
| Issue: |
2 |
| Pages: |
95-9 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Adler AS |
| Year: |
2006 |
| Journal: |
Nat Genet |
| Title: |
Genetic regulators of large-scale transcriptional signatures in cancer. |
| Volume: |
38 |
| Issue: |
4 |
| Pages: |
421-30 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Lindeman GJ |
| Year: |
1994 |
| Journal: |
Immunity |
| Title: |
B-lymphoid to granulocytic switch during hematopoiesis in a transgenic mouse strain. |
| Volume: |
1 |
| Issue: |
6 |
| Pages: |
517-27 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Kuehl WM |
| Year: |
2008 |
| Journal: |
Cancer Cell |
| Title: |
Modeling multiple myeloma by AID-dependent conditional activation of MYC. |
| Volume: |
13 |
| Issue: |
2 |
| Pages: |
85-7 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Borrello MG |
| Year: |
2008 |
| Journal: |
Cancer Lett |
| Title: |
Inflammation and cancer: the oncogene-driven connection. |
| Volume: |
267 |
| Issue: |
2 |
| Pages: |
262-70 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Beltran H |
| Year: |
2014 |
| Journal: |
Mol Cancer Res |
| Title: |
The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential. |
| Volume: |
12 |
| Issue: |
6 |
| Pages: |
815-22 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Mustachio LM |
| Year: |
2020 |
| Journal: |
Cancer Res |
| Title: |
Targeting the SAGA and ATAC Transcriptional Coactivator Complexes in MYC-Driven Cancers. |
| Volume: |
80 |
| Issue: |
10 |
| Pages: |
1905-1911 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Winkler R |
| Year: |
2022 |
| Journal: |
Cells |
| Title: |
Lessons from Using Genetically Engineered Mouse Models of MYC-Induced Lymphoma. |
| Volume: |
12 |
| Issue: |
1 |
|
|
•
•
•
•
•
|
| Publication |
| First Author: |
Le Good JA |
| Year: |
1998 |
| Journal: |
Science |
| Title: |
Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. |
| Volume: |
281 |
| Issue: |
5385 |
| Pages: |
2042-5 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Beringer M |
| Year: |
2016 |
| Journal: |
Mol Cell |
| Title: |
EPOP Functionally Links Elongin and Polycomb in Pluripotent Stem Cells. |
| Volume: |
64 |
| Issue: |
4 |
| Pages: |
645-658 |
|
•
•
•
•
•
|
| Protein |
| Organism: |
Mus musculus/domesticus |
| Length: |
369
 |
| Fragment?: |
false |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Comino-Méndez I |
| Year: |
2011 |
| Journal: |
Nat Genet |
| Title: |
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. |
| Volume: |
43 |
| Issue: |
7 |
| Pages: |
663-7 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Mejia-Martinez F |
| Year: |
2017 |
| Journal: |
Genes (Basel) |
| Title: |
The MXL-3/SBP-1 Axis Is Responsible for Glucose-Dependent Fat Accumulation in C. elegans. |
| Volume: |
8 |
| Issue: |
11 |
|
|
•
•
•
•
•
|
| Publication |
| First Author: |
Johnson DW |
| Year: |
2014 |
| Journal: |
PLoS Genet |
| Title: |
The Caenorhabditis elegans Myc-Mondo/Mad complexes integrate diverse longevity signals. |
| Volume: |
10 |
| Issue: |
4 |
| Pages: |
e1004278 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Casamayor A |
| Year: |
1999 |
| Journal: |
Curr Biol |
| Title: |
Functional counterparts of mammalian protein kinases PDK1 and SGK in budding yeast. |
| Volume: |
9 |
| Issue: |
4 |
| Pages: |
186-97 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Gräub R |
| Year: |
2003 |
| Journal: |
J Basic Microbiol |
| Title: |
Ksg1, a homologue of the phosphoinositide-dependent protein kinase 1, controls cell wall integrity in Schizosaccharomyces pombe. |
| Volume: |
43 |
| Issue: |
6 |
| Pages: |
473-82 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Bimbó A |
| Year: |
2005 |
| Journal: |
Mol Biol Cell |
| Title: |
Roles of Pdk1p, a fission yeast protein related to phosphoinositide-dependent protein kinase, in the regulation of mitosis and cytokinesis. |
| Volume: |
16 |
| Issue: |
7 |
| Pages: |
3162-75 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Alessi DR |
| Year: |
1997 |
| Journal: |
Curr Biol |
| Title: |
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. |
| Volume: |
7 |
| Issue: |
4 |
| Pages: |
261-9 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Currie RA |
| Year: |
1999 |
| Journal: |
Biochem J |
| Title: |
Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. |
| Volume: |
337 ( Pt 3) |
|
| Pages: |
575-83 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Di Blasio L |
| Year: |
2017 |
| Journal: |
Cancers (Basel) |
| Title: |
Serine/Threonine Kinase 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) as a Key Regulator of Cell Migration and Cancer Dissemination. |
| Volume: |
9 |
| Issue: |
3 |
|
|
•
•
•
•
•
|
| Publication |
| First Author: |
Gagliardi PA |
| Year: |
2018 |
| Journal: |
Semin Cancer Biol |
| Title: |
PDK1: At the crossroad of cancer signaling pathways. |
| Volume: |
48 |
|
| Pages: |
27-35 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Kobayashi T |
| Year: |
1999 |
| Journal: |
Biochem J |
| Title: |
Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. |
| Volume: |
339 ( Pt 2) |
|
| Pages: |
319-28 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Fiory F |
| Year: |
2005 |
| Journal: |
Mol Cell Biol |
| Title: |
Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by the insulin receptor is necessary for insulin metabolic signaling. |
| Volume: |
25 |
| Issue: |
24 |
| Pages: |
10803-14 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Mora A |
| Year: |
2005 |
| Journal: |
Biochem J |
| Title: |
Deficiency of PDK1 in liver results in glucose intolerance, impairment of insulin-regulated gene expression and liver failure. |
| Volume: |
385 |
| Issue: |
Pt 3 |
| Pages: |
639-48 |
|
•
•
•
•
•
|
| Protein Domain |
| Type: |
Family |
| Description: |
This family includes 3-phosphoinositide-dependent protein kinase 1 (PDK1 or PDPK1) and related kinases from yeast: Pkh1 and Pkh2 from S. cerevisiae, which function similarly to PDK1 [], and Ksg1 []and Ppk21 from S. pombe [].PDK1 is the kinase responsible for the phosphorylation of PKB/Akt on the activation loop, at threonine 308, which is essential for Akt activation [, ]. Beyond Akt, PDK1 is responsible for the phosphorylation of many other AGC kinases including serum/glucocorticoid regulated kinase (SGK) []and the members of protein kinase C (PKC) family []. PDK1 is implicated in signaling pathways frequently altered in cancer, such as PI3K/Akt, Ras/MAPK and Myc []. It is a key regulator of cell migration and tumor invasion []. PDK1 binds to the insulin receptor, followed by tyrosine phosphorylation of PDK1 by the insulin receptor, which is necessary for insulin metabolic signaling []. Deficiency of PDK1 in liver results in glucose intolerance []. |
|
•
•
•
•
•
|
| Protein Domain |
| Type: |
Family |
| Description: |
In mouse embryonic stem cells (mESCs), the transcriptional network can be divided into three functionally distinct modules: Polycomb, Core, and Myc, and the Polycomb module represses developmental genes []. This family includes the polycomb repressive complex 2-associated factor EPOP (Elongin BC and Polycomb Repressive Complex 2 (PRC2) Associated Protein, also termed C17orf96, esPRC2p48, E130012A19Rik), a scaffold protein expressed in the inner cell mass of the mouse blastocyst serving as a bridging partner between the PRC2/EED-EZH2 complex and the elongin BC complex, and fine-tuning the transcriptional status of Polycomb group (PcG) target genes in embryonic stem cells. Both EPOP and Elongin BC are required to maintain low levels of expression at PRC2 genomic targets []. EPOP interacts with the H2B deubiquitinase USP7 to modulate transcriptional processes in mESCs similar to MYC [].Another member of the family is the uncharacterized SKI/DACH domain-containing protein 1. |
|
•
•
•
•
•
|
| Protein Domain |
| Type: |
Family |
| Description: |
Protein max is a transcription regulator that forms a complex with MYC or MAD []. The MYC:MAX complex is a transcriptional activator, whereas the MAD:MAX complex is a repressor. MAX is also a component of the E2F6.com-1 []and MLL1 complexes []. Mutations in the MAX gene are associated with hereditary pheochromocytoma, which is a tumour of the chromaffin tissue of the adrenal medulla or sympathetic paraganglia resulting in hypertension [].This entry also includes Mxl-1 and Mxl-3 from Caenorhabditis elegans. Mxl-1 forms complexes with Mdl1. The Mdl-1:Mxl-1 complex functions in both the insulin signaling and dietary restriction pathways and is involved in the control of lifespan in response to dietary restriction []. Mxl-3 is a transcription factor that modulates the inhibition of lipolysis. It also regulates lipid metabolism during nutritional excess []. |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Ou XM |
| Year: |
2006 |
| Journal: |
Proc Natl Acad Sci U S A |
| Title: |
Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. |
| Volume: |
103 |
| Issue: |
29 |
| Pages: |
10923-8 |
|
•
•
•
•
•
|
| Protein |
| Organism: |
Mus musculus/domesticus |
| Length: |
438
 |
| Fragment?: |
false |
|
•
•
•
•
•
|
| Protein |
| Organism: |
Mus musculus/domesticus |
| Length: |
226
 |
| Fragment?: |
true |
|
•
•
•
•
•
|
| Protein |
| Organism: |
Mus musculus/domesticus |
| Length: |
308
 |
| Fragment?: |
true |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Chen K |
| Year: |
2005 |
| Journal: |
J Biol Chem |
| Title: |
R1, a novel repressor of the human monoamine oxidase A. |
| Volume: |
280 |
| Issue: |
12 |
| Pages: |
11552-9 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Bezsonova I |
| Year: |
2009 |
| Journal: |
Biochemistry |
| Title: |
Ring1B contains a ubiquitin-like docking module for interaction with Cbx proteins. |
| Volume: |
48 |
| Issue: |
44 |
| Pages: |
10542-8 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Chan TS |
| Year: |
2016 |
| Journal: |
Cancer Res |
| Title: |
JPO2/CDCA7L and LEDGF/p75 Are Novel Mediators of PI3K/AKT Signaling and Aggressive Phenotypes in Medulloblastoma. |
| Volume: |
76 |
| Issue: |
9 |
| Pages: |
2802-12 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Hendrix J |
| Year: |
2014 |
| Journal: |
J Biol Chem |
| Title: |
Dynamics of the ternary complex formed by c-Myc interactor JPO2, transcriptional co-activator LEDGF/p75, and chromatin. |
| Volume: |
289 |
| Issue: |
18 |
| Pages: |
12494-506 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Maertens GN |
| Year: |
2006 |
| Journal: |
J Cell Sci |
| Title: |
Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin. |
| Volume: |
119 |
| Issue: |
Pt 12 |
| Pages: |
2563-71 |
|
•
•
•
•
•
|